Evidence map›Paper›PMID 38213946›Full record

ArticlePulmonary circulation2024

BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension.

Shine Kumar, Lalitha Biswas, Anju Choorakottayil Pushkaran, Raman Krishna Kumar

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shine KumarDepartment of Pediatric Cardiology, Pulmonary Hypertension Clinic, Amrita Hospital Amrita Vishwa Vidyapeetham University Kochi Kerala India.ORCID 0000-0002-1050-9025
Lalitha BiswasAmrita Centre for Nanosciences and Molecular Medicine, Amrita Hospital Amrita Vishwa Vidyapeetham University Kochi Kerala India.
Anju Choorakottayil PushkaranAmrita Centre for Nanosciences and Molecular Medicine, Amrita Hospital Amrita Vishwa Vidyapeetham University Kochi Kerala India.
Raman Krishna KumarDepartment of Pediatric Cardiology, Pulmonary Hypertension Clinic, Amrita Hospital Amrita Vishwa Vidyapeetham University Kochi Kerala India.
Amrita Institute of Medical Sciences and Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone morphogenetic protein receptor 2 (BMPR2) mutation is the most common gene mutation implicated in the pathogenesis of pulmonary arterial hypertension (PAH). We describe, for the first time, an excellent clinical response to tyrosine kinase inhibitor imatinib in a patient with heritable PAH from BMPR2 mutation.

Indexed as

Bmpr2 mutationhereditaryimatinibpulmonary hypertension

Identifiers

PMID38213946
PMCPMC10782117
OpenAlexW4390742574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.